32 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
Exposure in Patients with Carcinoid Syndrome was Consistent with Expectations from Healthy Volunteers Healthy volunteer data is from paltusotine … -dose, 80 mg trough, and 80 mg post-dose, respectively. Healthy Volunteer Carcinoid Syndrome Patients
Paltusotine was Well-Tolerated with No Severe
8-K
EX-99.1
yyegf7rgrsz2e
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
lxl1ys
12 Aug 22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:41am
8-K
EX-99.1
9bapdtsjkgrt9sa94j1
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
oulna
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
8-K
EX-99.2
7b726obmqvawb2h
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
pbusp 6a2poefhacwumh
17 Mar 22
Other Events
6:22pm
8-K
EX-99.1
d79tx1rpzd p0n68wwc
5 Nov 21
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.2
2z6kyim
10 Aug 21
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:05pm
8-K
EX-99.1
7e5w78gvqul1tfuxhu
6 May 21
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results
4:01pm
424B5
3kpgyt3nv4a
8 Apr 21
Prospectus supplement for primary offering
4:07pm
8-K
qned41l
4 Feb 21
Other Events
7:00am